about
N-of-1 trials of expensive biological therapies: a third way?Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy.Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatmentInfliximab: 12 years of experienceUpdated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Immobilization of a human epidermal growth factor receptor 2 mimotope-derived synthetic peptide on Au and its potential application for detection of herceptin in human serum by quartz crystal microbalance.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.The safety of etanercept for the treatment of plaque psoriasis.Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Genetic variation associated with preterm birth: a HuGE review.Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis CConsistent control of psoriasis by continuous long-term therapy: the promise of biological treatments.Infliximab for the treatment of psoriasis.An unusual case of granulomatous lung disease. A clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery.Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.Arthritis in pregnancy: the role and safety of biological agents.Molecularly targeted therapies for dysimmune neuropathiesAdalimumab (TNF α Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient.Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.The use of antirheumatic disease drugs during pregnancy.Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6.Etanercept: efficacy and safety for approved indications.Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.Fullerenes and their derivatives as inhibitors of tumor necrosis factor-α with highly promoted affinities.Management of ankylosing spondylitis with infliximab.Suppression of antibody-mediated arthritis in mice by Fab fragments of the mediating antibodies.Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists.Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome.Infliximab-associated autoimmune limbic encephalitis: a case report.Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
P2860
Q30483827-3A2A334D-4EE9-42E0-A07F-09CB0C1F2200Q34078707-96372297-2949-45E9-8F81-904973918565Q34556944-B0284938-21C1-4CD5-983F-AC0EB8AE0326Q34653758-F4721E63-13D3-4C88-B158-504BBAB0BF2CQ34705364-8510D1DA-67C0-4832-92E8-F2D08C19D020Q35070446-4F73F57F-B67D-458B-B383-A09EC375475FQ35579352-B5B12303-5381-4BE4-8AAC-D5A1A0C1810BQ35579517-245CE945-B843-422E-B0B6-3715A37D0F62Q35603042-5747FD46-5832-4A7F-B908-D76A39A907EFQ35638252-9D9E761A-DABC-4274-B5AD-97334D72BFCFQ35919214-702BB52F-BCCB-4F6C-B739-2E9DB8762D11Q35954593-CC02B911-8255-47A2-9B4D-74F7E23E5C46Q36171750-88865D6E-D7C8-4391-8CDA-2388267F9430Q36319054-C0599237-4712-46EB-94EC-E604CC3C6221Q36522235-BB64C3F9-2906-4F28-9041-9884D20093A1Q36534231-73719B91-4930-4B58-9884-A361DC33496EQ36541961-C6DB5D52-BB92-49A8-8059-CDF1E60F6AD2Q36796493-9B6AB732-6B45-44BE-BE14-CFA5E64C07D4Q36847326-F84D8A32-D378-4E74-A4EC-3D5CD64E4DE5Q37186057-81194313-ADFD-44E2-8212-FFDF633E7609Q37254545-62EDC655-0F54-4491-B92E-5CE6ECE46042Q37556070-DCD9F796-DBD8-432B-8F44-FA824B029587Q37591474-D04FB881-424F-4D58-9161-9F9C3AE24B82Q37608422-55C6A6A3-F3FB-420C-9BC6-5EEC182EE67DQ37740229-FDED3EFD-63BA-4CF6-8473-7103F8A13978Q37954714-E11DD1F2-CD41-41FB-B48F-FBBFC87BEBD3Q37987077-63D44D10-FBF6-463A-81E3-CF737FE9C6FAQ38065099-409646FC-E793-4686-9D5B-412220264FF6Q38851521-326AFA1C-C835-4D8A-ACB3-64D577CC479CQ38993236-721846D6-F26A-4F43-A89D-EBAB3F304FBEQ41121882-2DDAC558-5D43-40D8-B7BD-D56DA571EC34Q41934387-4C1536F6-894E-4F32-A45C-DE7FEBE7B8D3Q42410013-07913158-FA94-4558-A024-0AA70530B51DQ43630443-A7E050A5-434F-4F27-90E1-B59C1E47E72BQ48700956-7FC0C5BF-A4CD-4DAD-959B-9EACA1B6D50AQ55693561-473C34E8-7EBC-4FC9-9D34-8A6D3AABDD70
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Safety of tumour necrosis factor-alpha antagonists.
@ast
Safety of tumour necrosis factor-alpha antagonists.
@en
type
label
Safety of tumour necrosis factor-alpha antagonists.
@ast
Safety of tumour necrosis factor-alpha antagonists.
@en
prefLabel
Safety of tumour necrosis factor-alpha antagonists.
@ast
Safety of tumour necrosis factor-alpha antagonists.
@en
P2093
P1433
P1476
Safety of tumour necrosis factor-alpha antagonists.
@en
P2093
Daniel E Furst
Dinesh Khanna
Maureen McMahon
P304
P356
10.2165/00002018-200427050-00003
P577
2004-01-01T00:00:00Z
P6179
1044224706